Poxel - Pharmaceutical Company set-up to find innovative solutions for metabolic diseases management with a primary focus on type 2 diabetes

News

June 2013Poxel and Pharsight presented a poster on IMEGLIMIN at the 2013 PAGE (Patient Approach Group Europe) meeting in Glasgow.

Information on the PAGE meeting

The objective of this work was to set up early on a PK and PKPD framework based on clinical endpoints (fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c)) in T2DM for Imeglimin, the first in a new, tetrahydrotriazine-containing class of oral antidiabetic agents, the Glimins.

Access to the poster

June 2012Key Opinion Leaders in Diabetology author a poster on Imeglimin add-on to metformin efficacy and tolerance.

The poster was presented at the 72nd scientific sessions of the American Diabetes Association meeting in Philadelphia 8-12 June.
This phase II trial did confirm Imeglimin additive effect to metformin in metformin failing patients. Imeglimin exhibited a positive tolerability and safety profile.

> Download the poster

June 2012Poxel and Pharsight present a poster at the 21st PAGE (Population Approach Group Europe) around PKPD modeling - Venice 5-8 June 2012.

Information on PAGE meeting.

The aim of the work was to predict a likely clinical efficacious dose for a new Poxel antidiabetic compound, with a new mechanism of action, based on in vitro activity data, PKPD modeling in ob/ob mice and glucose as single endpoint.

> Download the poster

March 2012Imeglimin mitochondrial activity confirmed on a model of hyperglycemic mice with septic shock.

The reknown asnethesiology team of Ulm university did present such data on the occasion of the International Symposium on Intensive Care and Emergency Medicine that took place in Brussels from March 20 to 23.

> Download the poster

October 2011Poxel SA announced that €1.45mio funding has been awarded by the French Public Financing Institution OSEO for two main programs targeting type 2 diabetes.

Imeglimin has been awarded a €950K refundable grant to support the phase 2 development package currently running at Poxel. A second program, targeting direct AMPK activation, has been granted up to €500K to enable the preclinical development start. This program is co-financed by the European Union. €250K are funded by the European Fund of Regional Development (FEDER) and €250K are a refundable grant from OSEO.

Europe is committed to the Rhône-Alpes region with the European Fund of Regional Development.

European flag

These funding reflect the confidence that OSEO puts on Poxel capabilities to progress the development of these 2 innovative programs. http://www.oseo.fr/

May 2011

Poxel and co-authors publish the 1st Imeglimin paper around this phase II product pharmacology

January 20112 new persons joined Poxel team

2 new persons joined Poxel team, Ms Rodica Orza to manage clinical trials and Mr Eric Massou who brings financial expertise

December 2010Poxel SA appoints Dynamics Group Communication Agency

Poxel SA appoints Dynamics Group Communication Agency (Geneva) to support its Corporate communication
www.dynamicsgroup.ch

July 2010Poxel Raises €16 million Financing

Poxel Raises €16 million in a Series A Financing to Accelerate Pipeline Development

September 2009NATHEB Project

Poxel earns €430,000 grant from public organizations for a cooperative project named NATHEB

Project co-financed by the European Union

Europe commits with the European Fund for Regional Development

Sitemap | Legal
© Poxel SA